2
Clinical Trials associated with LCAR-BCDR(Nanjing Legend Biotechnology)A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BCMA-targeted LCAR-BCDR Cells Product in Patients With Relapsed/Refractory Multiple Myeloma
This is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCDR cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy.
/ Unknown statusPhase 1IIT Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma
This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.
100 Clinical Results associated with LCAR-BCDR(Nanjing Legend Biotechnology)
100 Translational Medicine associated with LCAR-BCDR(Nanjing Legend Biotechnology)
100 Patents (Medical) associated with LCAR-BCDR(Nanjing Legend Biotechnology)
100 Deals associated with LCAR-BCDR(Nanjing Legend Biotechnology)